Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

Affiliations

I Kuchuk et al. Curr Oncol. 2012 Oct.

. 2012 Oct;19(5):e303-4.

doi: 10.3747/co.19.1009.

¹ Division of Medical Oncology, The Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, ON.

No abstract available

References

1. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast. 2007;16(suppl 3):S16–20. doi: 10.1016/j.breast.2007.10.005. - DOI - PubMed
1. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer. 2011;19:1687–96. doi: 10.1007/s00520-011-1230-9. - DOI - PubMed
1. Kuchuk I, Paterson A, Amir E, Clemons M, Bouganim N. Treatment recommendations for the use of bone-targeted agents in 2011—report from the 6th Annual Bone and the Oncologist New Updates meeting. Curr Oncol. 2012;19:364–370.
1. Ali SM, Demers LM, Leitzel K, et al. Baseline serum ntx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol. 2004;15:455–9. doi: 10.1093/annonc/mdh089. - DOI - PubMed
1. Bouganim N, Hilton JF, Vandermeer L, et al. A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer—the triumphtrial [abstract TPS242] J Clin Oncol. 2011;29 [Available online at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&c...; cited July 17, 2012]